Victory Pharma acquisition to boost Shionogi's pain ambitions
This article was originally published in Scrip
Executive Summary
The Shionogi group company Sciele Pharma is to acquire the private US firm Victory Pharma for $150 million to expand its presence in the pain management area. The deal is expected to close in the second quarter, subject to antitrust and other clearances.
You may also be interested in...
Santen Gains Ready-Made US Portfolio Via $225m Eyevance Buy
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Asia Deal Watch: Cancer Collaborations, Licensings Lead Activity In Asia
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Atlas, Rise! Japan Cancer Center Builds Asia Trial Network
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.
Need a specific report? 1000+ reports available
Buy Reports